AMW Reports Another Record Result for the 2024 Financial Year
Warngau, Germany, May 13, 2025
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today reported financial results for the year ended December 31, 2024. AMW posted another consolidated record revenue for 2024 of EUR 38.2 million, an increase of 30% compared to the previous year (2023: EUR 29.4 million). The Company once again increased its EBITDA for the year and thus achieved operating profitability for the third year in succession. For the financial year 2025, sales are expected to grow again in the double-digit percentage range with correspondingly significant positive effects on EBITDA.
The rise in revenues was mainly driven by increased sales of AMW’s implants goserelin and leuprorelin. Endomedica GmbH, AMW’s wholly owned subsidiary, and responsible for marketing leuprorelin as Leugon® in Germany, also contributed significantly to the Company’s overall revenues achieving the fourth consecutive sales record in a row. Due to a rise in productivity, the production volume was increased accordingly, thus enabling sales growth and increasing profitability.
“AMW is on course for growth, which is also reflected in our financial figures,” said Philipp Karbach, CEO of AMW. “We are very proud that not only our team is growing steadily, but that our sales and earnings also mirror this development. This is firstly owed to AMW’s strategy of consistently focusing on biodegradable implants. Secondly, I would like to explicitly thank our employees, whose commitment and tireless efforts make a decisive contribution to our success. I am therefore particularly pleased that so many of our employees have taken the opportunity to become shareholders as part of our ‘AMW Evolution program’. In addition, we managed to secure further financing options amounting to over EUR 10 million in the 2024 reporting year. We are therefore well equipped to continue pursuing our growth strategy at full speed this year.”
###
About AMW GmbH:
AMW is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW has two approved medical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW is based in Warngau near Munich, Germany.
For further information please contact:
AMW GmbH
Eva Hoffmann
Phone: +49 8024 470999-0
E-mail: news@amw-pharmaceuticals.com
